Cytek Biosciences (CTKB) EBT (2020 - 2026)

Cytek Biosciences (CTKB) has reported EBT for 7 consecutive years, with -$11.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBT fell 71.85% year-over-year to -$11.6 million; the trailing twelve-month figure through Jun 2026 stood at -$40.8 million (down 439.82% YoY), and the FY2025 full-year result was -$29.8 million, down 423.53% from the prior year.
• EBT advanced to -$11.6 million in Q2 2026 per CTKB's latest filing, from -$17.4 million in the prior quarter.
• Across five years, EBT topped out at $10.3 million in Q4 2024 and bottomed at -$17.4 million in Q1 2026.
• Historically, EBT has averaged -$4.4 million across 5 years, with a median of -$5.4 million in 2023.
• The sharpest annual moves came in 2022 and 2025: EBT surged 826.58% in 2022, then slumped 5048.41% in 2025.
• Over 5 years, EBT stood at $4.1 million in 2022, then declined by 0.07% to $4.1 million in 2023, then soared by 151.11% to $10.3 million in 2024, then sank by 139.05% to -$4.0 million in 2025, then plunged by 188.84% to -$11.6 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$11.6 million, -$17.4 million, and -$4.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.